Eli Lilly And Co (NYSE: LLY) is off to a relatively strong start to today’s trading session in the pre-market hours this morning after releasing real-world data. Of course, the data was positive, leading to excitement among investors who are pushing the stock on a run for the top as we speak. Today, we’ll talk about:
- The data release;
- what we’re seeing from LLY as a result; and
- what we’ll be watching for with regard to the stock ahead.
LLY Gains On Positive Data
As mentioned above, Ely Lilly is having a strong start to the trading session this morning after releasing data. The data came from the real-world EMPaglifozin compaRative effectIveness and SafEty (EMPRISE) study of Jardiance. The study is a dual effort by both LLY and Boehringer Ingelheim.
In a press release issued this morning, the companies said that initial results from EMPRISE showed Jardiance led to a reduction in relative risk of hospitalization for heart failure in the amount of 44% when compared to dipeptidyl peptidase-4 inhibitors in routine clinical practice in the United States.
The company also said that data mined from 35,000 patients with type 2 diabetes between August 2014 and September 2016 will be presented at the American Heart Association Scientific Sessions 2018. The company also said that the results of this analysis further support the findings from the EMPA-REG OUTCOME trial. This trial showed a 35% relative risk reduction in HHF when comparing Jardiance to placebo and when added to standard of care in people with type 2 diabetes and established cardiovascular disease.
In a statement, Sherry Martin M.D., vice president of medical affairs at Lilly Diabetes, a core business section at LLY, had the following to offer:
The Boehringer Ingelheim and Lilly Diabetes Alliance is committed to building a comprehensive clinical picture of Jardiance across the cardiovascular risk continuum in type 2 diabetes… Physicians need better options to help their patients avoid hospitalization for heart failure, and we are encouraged that these findings from EMPRISE complement cardiovascular results from the EMPA-REG OUTCOME trial. We are committed to further understanding whether Jardiance may have potential in this area and look forward to sharing the future results of the EMPRISE study.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of Eli Lilly, the news proved to be overwhelmingly positive. After all, the Jardiance data is strong, and the fact that it was chosen for a presentation at the American Association Scientific Sessions 2018 is a bode of confidence. So, it comeas as no surprise that excited investors are pushing the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:47), LLY is trading at $109.75 per share after a gain of $3.00 per share or 2.81% so far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on LLY. In particular, we’re interested in following the company’s ongoing work to bring Jardiance to the masses that need it as well as the company’s continued growth in currently approved treatment sales and efforts to expand its already robust clinical pipeline. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!